Bicycle Therapeutics - das liest sich gut

Seite 1 von 1
Neuester Beitrag: 21.12.23 11:31
Eröffnet am:18.12.23 20:31von: moneywork4.Anzahl Beiträge:3
Neuester Beitrag:21.12.23 11:31von: Balu4uLeser gesamt:1.541
Forum:Hot-Stocks Leser heute:7
Bewertet mit:


888 Postings, 1815 Tage moneywork4meBicycle Therapeutics - das liest sich gut

18.12.23 20:31
Third Quarter 2023 and Recent Highlights

   BT8009 Selected to Participate in U.S. Food and Drug Administration (FDA) Program to Expedite Commercial Manufacturing Readiness. In October, Bicycle Therapeutics announced the FDA selected BT8009 to participate in the new Chemistry, Manufacturing and Controls (CMC) Development and Readiness Pilot (CDRP) Program, which was created to facilitate CMC development for therapies with expedited clinical development timeframes, based on the anticipated clinical benefits of earlier patient access to the therapy. BT8009 is one of up to nine products selected for the inaugural cohort of the CDRP Program.

   Announced Expedited Clinical Development Plan and Regulatory Pathway for BT8009 in Metastatic (Urothelial) Bladder Cancer. In September, Bicycle Therapeutics announced the company will proceed with its plan to expedite development of BT8009 for metastatic bladder cancer following recent discussions with the FDA. The company aligned with the FDA on a Phase 2/3 registrational trial, called Duravelo-2, that has an innovative design allowing for potential accelerated approval in untreated (first-line) and previously treated (second-line plus) metastatic bladder cancer. The company plans to initiate the Duravelo-2 trial in the first quarter of 2024.
       In Cohort 1, two doses of BT8009 plus standard pembrolizumab regimen will be initially assessed. Following selection of the optimal dose, BT8009 plus pembrolizumab will be evaluated against chemotherapy. Potential accelerated approval will be determined by objective response rate (ORR), and progression-free survival (PFS) will be used to confirm clinical benefit.
       In Cohort 2, two doses of BT8009 as monotherapy will be initially studied. Following selection of the optimal dose, an additional arm of BT8009 plus standard pembrolizumab regimen will be added. Potential accelerated approval for BT8009 monotherapy and in combination with pembrolizumab will be determined by ORR compared to historical control data. Discussions with the FDA about the design of the confirmatory trial for previously treated metastatic bladder cancer are ongoing.

   Raised Net Proceeds of $215.1 Million in Public Offering. In July, Bicycle Therapeutics announced the closing of an underwritten public offering resulting in gross proceeds of approximately $230.0 million, including the full exercise of the underwriters' option to purchase additional shares. Net proceeds were approximately $215.1 million. In addition, the company also received net proceeds from Bicycle's at-the-market (ATM) offering program during the third quarter of 2023 totaling $19.4 million.

Cash eingesammelt, starke Partner und starke Pipeline!  

1 Posting, 191 Tage BBOATDrinbleibe

18.12.23 20:57
Bin seit mehr als 3 Jahren drin unter heftigen ups und downs. Aber so ist das bei den Biotechs. Drinbleiben! Mit ihrer Pipeline radeln sie zum Beispiel Bayer locker davon.  


23549 Postings, 5127 Tage Balu4uAuf jeden Fall ein interessanter Wert

21.12.23 11:31
Bin auch seit Kurzem dabei. Der Chart war zu verlockend, gepaart mit all dem was Money hier gepostet hat finde ich das ist ne Aktie für den Turnaround  

   Antwort einfügen - nach oben